Glaucoma warning
Use caution if you have glaucoma or increased eye pressure.
Leaflet ANORO 55mcg / 22mcg inhalation powder
- Product code:
- W60979001
- Quantity:
- 1
- Indicated for:
- chronic obstructive pulmonary disease
- Route of administration:
- inhalation
- Substance:
- umeclidinium + vilanterol (antimuscarinic bronchodilator + beta-2 adrenergic agonist)
- ATC
- R03AL03 — Respiratory system | Adrenergics, inhalants | Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Precautions:
Anticholinergic effects
May cause dry mouth, constipation, urinary retention, or blurred vision.
Hyperglycemia
This medicine may increase blood sugar.
Elderly warning
Older people may have an increased risk of side effects.
Cardiac risk / QT prolongation / arrhythmias
This medicine may increase the risk of heart rhythm disturbances.
Umeclidinium + vilanterol is a combination medication used for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This combination contains umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta-2 adrenergic agonist (LABA).
Umeclidinium works by relaxing the smooth muscles in the airways, reducing bronchoconstriction, while vilanterol improves airflow by stimulating beta-2 adrenergic receptors. Together, these medications help alleviate symptoms such as shortness of breath and coughing, improving the quality of life for patients with COPD.
The medication is administered via inhaler, once daily, as directed by a physician. Common side effects include headache, throat irritation, and upper respiratory tract infections. In rare cases, allergic reactions or worsening respiratory symptoms may occur.
Umeclidinium + vilanterol is an effective therapeutic option for long-term management of COPD, helping to reduce exacerbations and improve lung function.
Umeclidinium works by relaxing the smooth muscles in the airways, reducing bronchoconstriction, while vilanterol improves airflow by stimulating beta-2 adrenergic receptors. Together, these medications help alleviate symptoms such as shortness of breath and coughing, improving the quality of life for patients with COPD.
The medication is administered via inhaler, once daily, as directed by a physician. Common side effects include headache, throat irritation, and upper respiratory tract infections. In rare cases, allergic reactions or worsening respiratory symptoms may occur.
Umeclidinium + vilanterol is an effective therapeutic option for long-term management of COPD, helping to reduce exacerbations and improve lung function.
General data about ANORO 55mcg / 22mcg
- Substance:
- umeclidinium + vilanterol
- Date of latest medicines list:
- 01-07-2015
- Product code:
- W60979001
- Concentration:
- 55mcg / 22mcg
- Pharmaceutical form:
- inhalation powder
- Quantity:
- 1
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.